The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The somatic mutation landscape of germline CHEK2-altered prostate cancer.
 
Emily Nizialek
No Relationships to Disclose
 
Tamara L. Lotan
Consulting or Advisory Role - Janssen
Research Funding - DeepBio; Ventana Medical Systems
 
William B. Isaacs
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Srinivasan Yegnasubramanian
Stock and Other Ownership Interests - Brahm Astra Therapeutics; Digital Harmonic
Consulting or Advisory Role - Cepheid
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Cepheid (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: "Induction of synthetic lethality with epigenetic therapy"; Patent: "Agents for reversing epigenetic silencing of genes"; Patent: "Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations"; Patent: "DNA methylation markers for metastatic prostate cancer"; Patent: COMPARE-MS: A novel technique for rapid, sensitive, and accurate detection of DNA methylation
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi